Advances in Cancer Drug Targets

Volume 3

by

Atta-ur-Rahman

DOI: 10.2174/97816810823321160301
eISBN: 978-1-68108-233-2, 2016
ISBN: 978-1-68108-234-9
ISSN: 2451-8891 (Print)
ISSN: 2213-9915 (Online)



Recommend this eBook to your Library



Advances in Cancer Drug Targets is an e-book series that brings together recent...[view complete introduction]

Table of Contents

Preface

- Pp. i-ii (2)

Atta-ur-Rahman

Download Free

List of Contributors

- Pp. iii-v (3)

Atta-ur-Rahman

Download Free

Neutrophil Elastase as a Target in Lung Cancer: the State of the Art

- Pp. 3-49 (47)

Gautier Moroy, Alain J.P. Alix, Janos Sapi, William Hornebeck and Erika Bourguet

View Abstract Purchase Chapter

Inhibition of Membrane Complement Inhibitor Expression (CD46, CD55, CD59) by siRNA Sensitizes Tumor Cells to Complement Attack

- Pp. 50-77 (28)

Srinivas Mamidi, Simon Höne, Nicolas Geis, Stefanie Zell, Renate Rutz, Wenhan Li, Thomas Giese, Stefan Schultz and Michael Kirschfink

View Abstract Purchase Chapter

Points of Therapeutic Intervention along the Wnt Signaling Pathway in Hepatocellular Carcinoma

- Pp. 78-117 (40)

Miran Kim and Jack R. Wands

View Abstract Purchase Chapter

Collaboration of Epithelial Mesenchymal Transition and Cancer Stem Cells: Sinister Routes for Chemoresistant Recurrent Ovarian Cancer

- Pp. 118-155 (38)

N. Ahmed, K. Abubaker, E. Chan, G. Kannourakis and J.K. Findlay

View Abstract Purchase Chapter

Oxaliplatin-mediated Inhibition of Survivin Increases Sensitivity of Head and Neck Squamous Cell Carcinoma Cell Lines to Paclitaxel

- Pp. 156-180 (25)

P.S. Bisen, Z. Khan, N. Khan and G.B.K.S. Prasad

View Abstract Purchase Chapter

Melatonin Inhibits the Growth of DMBA-induced Mammary Tumors by Regulating Estrogen Sulfatase Enzyme

- Pp. 181-206 (26)

Alicia González, Virginia Álvarez-García, Carlos Martínez-Campa, Carolina Alonso-González and Samuel Cos

View Abstract Purchase Chapter

Role of mTOR Signaling in Tumor Cell Motility, Invasion and Metastasis

- Pp. 207-244 (38)

Hongyu Zhou and Shile Huang

View Abstract Purchase Chapter

Structure-Activity Studies on Arylamides and Arysulfonamides Ras Inhibitors

- Pp. 245-264 (20)

Sonia Colombo, Alessandro Palmioli, Cristina Airoldi, Renata Tisi, Sonia Fantinato, Sandro Olivieri, Luca De Gioia, Enzo Martegani and Francesco Peri

View Abstract Purchase Chapter

Subject Index

- Pp. 265-266 (2)

Atta-ur-Rahman

Download Free

Preface

The 3rd volume of the book Series “Advances in Cancer Drug Targets” comprises eight chapters written by the leading experts in this field. It is an outstanding collection of well written chapters on cancer drug targets in the field of pharmacology, molecular biology and biochemistry.

Human neutrophil elastase (HNE) plays an important role in the development of chronic obstructive pulmonary diseases. In chapter 1, Alix et al., explain its involvement in non-small cell lung cancer progression. Natural compounds and/or synthesized agents which antagonize HNE activity have been comprehensively reviewed in this chapter. They also focus on substances (i.e. lipids and derivatives, phenolics) that exhibit an inhibitory bifunctionality towards HNE and matrix metalloproteinases (MMPs), particularly MMP-2.

The efficacy of cancer-immunotherapy with complement-activating monoclonal antibodies is restricted by over-expression of one or more membrane-bound complement regulatory proteins (mCRPs: CD46, CD55, CD59) that are present on the surface of neoplastic cells. Kirschfink et al., in chapter 2 discuss small interfering RNAs (siRNAs) for posttranscriptional gene knock down of CD46, CD55 and CD59 aiming to sensitize tumor cells.

Hepatocellular carcinoma (HCC) is the third most common cause of deaths from cancer worldwide. There is growing evidence that the deregulation of Wnt/β-catenin signaling pathway plays a critical role in hepatic oncogenesis and mainly occurs at the early stage of hepatocarcinogenesis. In chapter 3, Kim and Wands have summarized the potential molecular targets related to the Wnt/β-catenin signaling pathway along with their therapeutic applications.

A major challenge in treating ovarian cancer is to overcome intrinsic and acquired. Chapter 4 by Ahmed et al. presents the recent advances in our understanding of the cellular origin and the molecular mechanisms defining the basis of cancer initiation and malignant transformation with respect to epithelial-mesenchymal transition (EMT) of ovarian cancer cells.

Due to the high expression of Survivin in various carcinomas, it is one of the key antiapoptotic proteins. It is also associated with their biologically aggressive characteristics and drug resistance. Bisen et al., in chapter 5 elaborate the efficacy of combination of oxaliplatin and paclitaxel as a potential strategy in controlling HNSCC cell proliferation. This review highlights the fact that the co-treatment of cells with paclitaxel and oxaliplatin results in a significantly higher cytotoxicity as compared to individual single drug treatment.

Melatonin has oncostatic effects on different neoplasias, particularly on estrogen-dependent breast cancer. The compound acts by interacting with estrogen-responsive pathways, thus behaving as an antiestrogenic hormone. In chapter 6 by Cos et al., evidence is presented that that melatonin could exert its antitumoral effects on hormone-dependent mammary tumors by down-regulating the sulfatase pathway of the tumoral tissue.

Recent studies have thrown light on the role of mammalian target of rapamycin (mTOR) in the regulation of tumor cell motility, invasion and cancer metastasis. Zhou and Huang in chapter 7 discuss the mTOR complexes and the role of mTOR signaling in tumor cell migration and invasion. The chapter also highlights the findings about the mechanism by which rapamycin inhibits cell migration, invasion and cancer metastasis.

It has been hypothesised that a phenyl hydroxylamine group linked to a second aromatic moiety generates a pharmacophore which can interact with Ras and inhibit its activation In chapter 8, Peri et al., present reports on the synthesis of a library of small molecules with arylamides and arylsulfonamides groups. They also explain their biological activity to inhibit nucleotide exchange on human Ras.

I hope that the current book volume, which provides insights into the development of new approaches to anti-cancer therapy for interested researchers and pharmaceutical scientists, will be received with the same enthusiasm as the previous volumes of this Series. I am grateful to the valuable contributions made by the authors. I greatly appreciate the assistance from the editorial staff, particularly Mr. Mahmood Alam (Director Publications) and Mr. Shehzad Naqvi (Senior Manager) for their hard work and determined efforts.

Prof. Atta-ur-Rahman, FRS
Honorary Life Fellow
Kings College
University of Cambridge
UK

List of Contributors

Editor(s):
Atta-ur-Rahman
Kings College, University of Cambridge
Honorary Life Fellow
Cambridge
UK




Contributor(s):
Alain J.P. Alix
Institut de Chimie Moléculaire de Reims & Laboratoire de Spectroscopies et Structures Biomoléculaires
Faculté des Sciences, IFR53 Biomolécules, BP 1039, 51687
Université de Reims Champagne-Ardenne, CNRS UMR 6229
Reims Cedex
France


Alessandro Palmioli
Department of Biotechnology and Biosciences
University of Milano-Bicocca
Piazza della Scienza 2, 20126
Milano
Italy


Alicia Gonzlez
Department of Physiology and Pharmacology
School of Medicine, University of Cantabria and Instituto de Investigación Valdecilla (IDIVAL)
39011 Santander
Spain


E. Chan
Department of Obstetrics and Gynaecology
University of Melbourne
Melbourne
Australia


Carolina Martínez-Campa
Department of Physiology and Pharmacology
School of Medicine, University of Cantabria and Instituto de Investigación Valdecilla (IDIVAL)
39011 Santander
Spain


Cristina Airoldi
Department of Biotechnology and Biosciences
University of Milano-Bicocca
Piazza della Scienza 2, 20126
Milano
Italy


Enzo Martegani
Department of Biotechnology and Biosciences
University of Milano-Bicocca
Piazza della Scienza 2, 20126
Milano
Italy


Erika Bourguet
Institut de Chimie Moléculaire de Reims, Faculté de Pharmacie, IFR53 Biomolécules, 51 rue de Cognacq-Jay
Université de Reims Champagne-Ardenne, CNRS UMR 6229
51096 Reims Cedex
France


Francesco Peri
Department of Biotechnology and Biosciences
University of Milano-Bicocca
Piazza della Scienza 2, 20126
Milano
Italy


G. Kannourakis
Fiona Elsey Cancer Research Institute
Ballarat
Australia
/
Federation University
Ballarat
Australia


G.B.K.S. Prasad
School of Studies in Biochemistry
Jiwaji University
Gwalior 474011
India


Giese Thomas
Institute of Immunology, University of Heidelberg
Heidelberg
Germany


Hongyu Zhou
Department of Biochemistry and Molecular Biology
Louisiana State University, Health Sciences Center
1501 Kings Highway
Shreveport
LA, 71130-3932
USA


J.K. Findlay
Department of Obstetrics and Gynaecology
University of Melbourne
Melbourne
Australia
/
Hudson Institute of Medical Research
Melbourne
Australia


Jack R. Wands
Institute of Immunology
Rhode Island Hospital and the Warren Alpert Medical School of Brown University
Providence, RI
USA


Janos SAPI
Institut de Chimie Moléculaire de Reims & Laboratoire de Spectroscopies et Structures Biomoléculaires, Faculté des Sciences
IFR53 Biomolécules, BP 1039, 51687, Université de Reims Champagne-Ardenne, CNRS UMR 6229
Reims Cedex
France


K. Abubaker
Department of Obstetrics and Gynaecology
University of Melbourne
Melbourne
Australia


Luca De Gioia
Department of Biotechnology and Biosciences
University of Milano-Bicoccaz
Piazza della Scienza 2, 20126
Milano
Italy


Michael Kirschfink
Institute of Immunology, University of Heidelberg
Heidelberg
Germany


Miran Kim
Institute of Immunology
Rhode Island Hospital and the Warren Alpert Medical School of Brown University
Providence, RI
USA


Moroy Gautier
Molécules thérapeutiques in silico
Université Paris Diderot
INSERM UMRS-973
Bât


N. Ahmed
Fiona Elsey Cancer Research Institute
Ballarat
Australia
/
Department of Surgery, University of Melbourne
Melbourne
Australia
/
Department of Obstetrics and Gynaecology
University of Melbourne
Melbourne
Australia
/
Hudson Institute of Medical Research
Melbourne
Australia


N. Khan
Division of Plant-Microbe Interactions
National Botanical Research Institute
Rana Pratap Marg, Lucknow
India


Nicolas Geis
Institute of Immunology
University of Heidelberg
Heidelberg
Germany


P. S. Bisen
School of Studies in Biotechnology
Jiwaji University
Gwalior 474011
India


Renate Rutz
Institute of Immunology
University of Heidelberg
Heidelberg
Germany


Renata Tisi
Department of Biotechnology and Biosciences
University of Milano-Bicocca
Piazza della Scienza 2, 20126
Milano
Italy


Samuel Cos
Department of Physiology and Pharmacology, School of Medicine
University of Cantabria and Instituto de Investigación Valdecilla (IDIVAL)
39011 Santander
Spain


Sandro Olivieri
Department of Biotechnology and Biosciences
University of Milano-Bicocca
Piazza della Scienza 2, 20126
Milano
Italy


Shile Huang
Department of Biochemistry and Molecular Biology
Health Louisiana State University
Sciences Center, 1501 Kings Highway
Shreveport
LA, 71130-3932
USA
/
Feist-Weiller Cancer Center, Louisiana State University
Health Louisiana State University
Sciences Center, 1501 Kings Highway
Shreveport
LA, 71130-3932
USA


Simon Höne
Institute of Immunology
University of Heidelberg
Heidelberg
Germany


Sonia Colombo
Department of Biotechnology and Biosciences
University of Milano-Bicocca, Piazza della Scienza 2, 20126
Milano
Italy


Sonia Fantinato
Department of Biotechnology and Biosciences
University of Milano-Bicocca, Piazza della Scienza 2, 20126
Milano
Italy


Srinivas Mamidi
Institute of Immunology
University of Heidelberg
Heidelberg
Germany


Stefanie Zell
Institute of Immunology
University of Heidelberg
Heidelberg
Germany


Stefan Schultz
Institute of Immunology
University of Heidelberg
Heidelberg
Germany


Virginia álvarez-García
Department of Physiology and Pharmacology, School of Medicine
University of Cantabria and Instituto de Investigación Valdecilla (IDIVAL)
39011 Santander
Spain


Wenhan Li
Institute of Immunology
University of Heidelberg
Heidelberg
Germany


William Hornebeck
Institut de Chimie Moléculaire de Reims, Faculté de Pharmacie, IFR53 Biomolécules, 51 rue de Cognacq-Jay
Université de Reims Champagne-Ardenne, CNRS UMR 6229
51096 Reims Cedex
France


Z. Khan
Department of Biomedical Sciences and Pathology and Laboratory Medicine
Cedars-Sinai Medical Center
Los Angeles
CA, 90048
USA




Advertisement


Related Journals



Related Books



Webmaster Contact: info@benthamscience.org Copyright © 2017 Bentham Science